ERYTECH Pharma S.A. (ERYP) Bundle
A Brief History of ERYTECH Pharma S.A. (ERYP)
Foundation and Early Development
Foundation and Early Development
ERYTECH Pharma S.A. was founded in 2004 in Lyon, France, by Dr. Gil Beyen and Dr. Renaud Aissani. The company specializes in developing innovative treatments for severe forms of cancer and orphan diseases using its unique technology platform based on red blood cells.
Initial Public Offering
In July 2013, ERYTECH Pharma went public on the Euronext Paris stock exchange, raising approximately €23.5 million ($31 million) in its IPO.
Listing on NASDAQ
In March 2018, the company expanded its reach by listing on the NASDAQ under the ticker symbol ERYP. The initial listing price was $8.00 per share.
Key Product Development – Erythrocyte Encapsulation Technology
ERYTECH is known for its proprietary ERYTECH technology platform, which encapsulates therapeutic drugs within red blood cells to improve their efficacy and reduce side effects. This technology is aimed at treating life-threatening diseases, with a focus on patients who have limited treatment options.
Clinical Trials and Milestones
- In 2019, ERYTECH’s lead product, Graspa, a L-asparaginase therapy for acute lymphoblastic leukemia (ALL), received Orphan Drug Designation from the FDA.
- In July 2021, the company reported results from the Phase 3 clinical trial of Graspa. The trial did not meet its primary endpoint.
- In December 2021, ERYTECH announced plans to cease the development of Graspa for ALL due to disappointing results.
Financial Performance
As of Q3 2023, ERYTECH reported a revenue of approximately €3.5 million ($4 million) primarily from grants and collaborations. The net loss for the same period was approximately €9 million ($10 million).
| Year | Revenue (€ million) | Net Loss (€ million) | Market Capitalization (€ million) |
|---|---|---|---|
| 2020 | 5.1 | 19.4 | 115 |
| 2021 | 3.8 | 23.1 | 130 |
| 2022 | 2.5 | 18.2 | 90 |
| 2023 (Q3) | 3.5 | 9.0 | 45 |
Recent Developments and Future Strategies
In 2022, ERYTECH announced its strategic decision to focus on the development of its pipeline products, particularly those targeting rare diseases. The company is currently assessing new partnerships and collaborations to strengthen its product offering and improve market positioning.
Leadership and Organizational Structure
Dr. Gil Beyen serves as the CEO. The executive team is supported by an experienced board with backgrounds in pharmaceuticals, biotechnology, and medical devices.
Conclusion of Historical Timeline
The journey of ERYTECH Pharma has been marked by significant developments and challenges. The company continues to engage in research and development aimed at providing innovative therapies for patients with serious diseases.
A Who Owns ERYTECH Pharma S.A. (ERYP)
Shareholder Structure
As of the latest available data, ERYTECH Pharma S.A. has a diverse shareholder structure, comprising institutional investors, individual shareholders, and company executives.
| Shareholder Type | Percentage Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 45% | 4,500,000 |
| Individual Shareholders | 30% | 3,000,000 |
| Company Executives and Directors | 15% | 1,500,000 |
| Others | 10% | 1,000,000 |
Major Shareholders
The following table lists the major shareholders of ERYTECH Pharma S.A. along with their respective ownership stakes.
| Shareholder Name | Percentage Ownership | Number of Shares |
|---|---|---|
| HealthCap VI L.P. | 10% | 1,000,000 |
| FMR LLC (Fidelity) | 8% | 800,000 |
| Walden Riverwood Ventures | 6% | 600,000 |
| Neuberger Berman Group LLC | 5% | 500,000 |
| Other Institutional Investors | 16% | 1,600,000 |
Board of Directors
The composition of the Board of Directors impacts the governance of ERYTECH Pharma. The following table details the current board members and their stakes in the company.
| Director Name | Position | Percentage Ownership |
|---|---|---|
| Yves P. Ribeill | Chairman | 2% |
| Jacques L. Besson | Director | 1% |
| Antoine P. A. H. Custot | Director | 1% |
| Marie Josée M. F. Bouchard | Director | 1% |
Market Capitalization
The market capitalization of ERYTECH Pharma S.A. is an important indicator of its financial health. As of the latest reports, the market cap is approximately €90 million.
Recent Financial Performance
The financial performance is reflected in the company’s recent earnings reports. Here are some key metrics:
| Metric | Amount |
|---|---|
| Total Revenue (2023) | €5.6 million |
| Net Income (2023) | (€20 million) |
| Total Assets | €85 million |
| Total Liabilities | €30 million |
Recent Developments
In 2023, ERYTECH Pharma announced a series of strategic partnerships which are expected to influence ownership dynamics and market positioning.
- Partnership with a major pharmaceutical company.
- Launch of a clinical trial for their lead product.
- Investment from new venture capital firms.
ERYTECH Pharma S.A. (ERYP) Mission Statement
Company Overview
ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer and orphan diseases. The company utilizes its proprietary technology platform that encapsulates therapeutic drugs in red blood cells to enhance efficacy and reduce toxicity.
Mission Statement
The mission of ERYTECH Pharma S.A. is to develop safer and more effective treatments for patients suffering from serious medical conditions, particularly cancer and rare diseases, leveraging their proprietary technology.
Core Values
- Innovation: Striving for breakthroughs in therapeutic development.
- Integrity: Commitment to ethical practices in research and clinical trials.
- Patient-Centric: Focusing on the needs and well-being of patients.
- Collaboration: Engaging with partners and stakeholders for collective advancements.
- Excellence: Pursuing high standards in all aspects of operations.
Strategic Goals
ERYTECH aims to:
- Advance the clinical development of ERY-ASP for the treatment of acute lymphoblastic leukemia (ALL).
- Expand its pipeline to include additional indications and collaborations.
- Enhance operational efficiencies to drive sustainable growth.
Recent Financial Highlights
As of Q3 2023, ERYTECH reported the following financial metrics:
| Metric | Q3 2023 Amount |
|---|---|
| Cash and Cash Equivalents | €24.5 million |
| Net Loss | €8.3 million |
| Revenue | €0.5 million |
| R&D Expenses | €6.0 million |
| Operating Expenses | €8.6 million |
Clinical Pipeline
ERYTECH's pipeline includes the following products in various stages of development:
| Product | Indication | Stage |
|---|---|---|
| ERY-ASP | Acute Lymphoblastic Leukemia | Phase 3 |
| ERY-ASP | Pancreatic Cancer | Phase 2 |
| ERY-Pharma | Orphan Diseases | Preclinical |
Market Potential
The market for cancer therapeutics is projected to reach $227.6 billion by 2024, presenting substantial opportunities for ERYTECH's innovative approach to treatment.
Conclusion of Financial Performance
ERYTECH Pharma is focused on maintaining strong financial health while driving innovation and expanding its product offerings in a competitive market.
How ERYTECH Pharma S.A. (ERYP) Works
Business Model
ERYTECH Pharma S.A. operates in the biopharmaceutical industry with a focus on developing and commercializing innovative therapies for cancer and orphan diseases. The company utilizes its patented technology platform to encapsulate therapeutic compounds in red blood cells, enhancing their efficacy and reducing side effects.
Key Products
The primary product of ERYTECH Pharma is ERY-ASP, an asparaginase therapeutic for treating acute lymphoblastic leukemia (ALL). As of 2023, ERY-ASP is in phase 3 clinical trials in the United States and Europe.
| Product | Indication | Phase | Projected Launch |
|---|---|---|---|
| ERY-ASP | Acute Lymphoblastic Leukemia | Phase 3 | 2024 |
Financial Data
As per the latest financial reports, ERYTECH Pharma’s revenue for the year 2022 was approximately €3.5 million, with a net loss of €20.2 million. The company had cash and cash equivalents amounting to €18.7 million as of December 31, 2022.
| Financial Metric | 2022 | 2021 |
|---|---|---|
| Revenue (€ million) | 3.5 | 2.9 |
| Net Loss (€ million) | (20.2) | (18.5) |
| Cash and Cash Equivalents (€ million) | 18.7 | 23.2 |
Clinical Trials
ERYTECH Pharma is conducting several clinical trials to assess the efficacy and safety of ERY-ASP. The most significant trial, titled ERY-ASP-003, aimed at evaluating the drug's effectiveness in pediatric patients.
Collaborations and Partnerships
The company has formed strategic partnerships with various research institutions and pharmaceutical companies to enhance its research and development capabilities.
- Collaboration with Sanofi for the development of ERY-ASP.
- Partnership with Institut Paoli-Calmettes for clinical research.
Market Potential
The global market for cancer therapeutics is projected to reach approximately €200 billion by 2025. The addressable market for ERY-ASP in the treatment of ALL is estimated to be €1 billion.
Stock Performance
As of October 2023, the stock price of ERYTECH Pharma (ERYP) is €3.20 per share. The company's market capitalization is approximately €107 million based on the total shares outstanding.
| Stock Data | Value |
|---|---|
| Current Price (€) | 3.20 |
| Market Capitalization (€ million) | 107 |
| 52-week Range (€) | 2.50 - 4.80 |
Future Outlook
With ongoing clinical trials and potential product launches, ERYTECH Pharma aims to strengthen its position in the oncology market. The company plans to expand its portfolio and explore additional indications for its technology platform.
How ERYTECH Pharma S.A. (ERYP) Makes Money
Revenue Generation Sources
ERYTECH Pharma S.A. primarily generates revenue through the development and commercialization of its innovative treatments for acute leukemia and other blood-related disorders. The company employs a specialized technology for encapsulating therapeutic enzymes, which enhances the efficacy and delivery of drugs. The following categories outline the company's revenue sources:
- Sales of approved therapies
- Partnerships and collaborations
- Grants and funding for research
- Licensing agreements
Sales of Approved Therapies
As of the latest financial report, ERYTECH Pharma has received marketing authorization for its lead product, Graspa (erythrocyte-encapsulated L-asparaginase), in the European Union, specifically for the treatment of certain types of acute lymphoblastic leukemia.
| Year | Product Sales (€ millions) |
|---|---|
| 2021 | 2.5 |
| 2022 | 5.0 |
| 2023 (Q1) | 1.2 |
Partnerships and Collaborations
ERYTECH engages in strategic partnerships to enhance its research and development capabilities. These collaboration agreements often include upfront payments, milestone payments, and royalties on sales. Recent partnerships include:
- Collaboration with the National Cancer Institute (NCI) for research projects
- Agreement with a major pharmaceutical company for co-development
For instance, a recent multi-million Euro partnership agreement could involve an upfront payment of €10 million, alongside milestone payments that could total up to €50 million depending on the progress of clinical trials.
Grants and Funding for Research
In addition to revenue from sales and partnerships, ERYTECH Pharma benefits from grants and funding provided by government and research organizations to support its clinical trials and R&D efforts. Notable grants include:
| Year | Grant Amount (€ millions) |
|---|---|
| 2021 | 1.5 |
| 2022 | 2.0 |
| 2023 | 0.7 |
Licensing Agreements
Licensing agreements are a significant source of potential revenue for ERYTECH. Through these deals, the company allows other firms to use its proprietary technologies in exchange for licensing fees and royalties. For example:
- Licensing of technology for use in specific oncology drug formulations
- Royalty agreements based on future product sales
In 2022, ERYTECH reported licensing income amounting to approximately €3 million, which was expected to increase with the expansion of its product pipeline.
Financial Performance Overview
As of the last fiscal report, ERYTECH Pharma had the following financial metrics:
| Metric | Value (€ millions) |
|---|---|
| Total Revenue | 7.5 |
| Operating Expenses | 15.0 |
| Net Loss | (7.5) |
| Cash Reserves | 20.0 |
ERYTECH Pharma S.A. (ERYP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support